Online CME

Series Activities

Series Activities

Cleveland Clinic Tumor Boards

Current Approaches to the Treatment of Metastatic Castration-Resistant Prostate Cancer

Print this Content

Release Date:   February 23, 2018
Expiration Date:   February 23, 2019

Estimated Time of Completion:   1 hour 15 minutes


The Current Approaches to the Treatment of Metastatic Castration-Resistant Prostate Cancer webcast reviews and discusses the evolving changes in the management of men with locally advanced and metastatic prostate cancer. Using real-life clinical cases as a platform, the expert faculty roundtable will discuss existing and emerging data that all practitioners can use to maximize the outcome of men with advanced disease.

Learning Objectives

  1. Discuss different treatment options for men with metastatic castrate-resistant prostate cancer (mCRPC).
  2. Summarize recent clinical trial data supporting FDA approval of various agents in this patient population.
  3. Distinguish between predictive and prognostic biomarkers and understand the purpose of each.
  4. Identify clinical biomarkers for men with mCRPC undergoing treatment with docetaxel.
  5. Highlight the prognostic implications of circulating tumor cells (CTCs) and AR-V7 expression in these cells.

Target Audience

This online series is designed for medical, radiation, and surgical oncologists, urologists, oncology practice managers, doctors of nursing practice, nurse practitioners, physician assistants, oncology clinical pharmacists, oncology advanced practice nurses, and other clinicians involved in oncology care delivery.


The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors and Faculty

Activity Directors

Jame Abraham, MD
Director, Breast Oncology Program
Co-Director, Comprehensive Breast Cancer Program
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Jorge A. Garcia, MD, FACP
The Kerscher Family Chair for Clinical Prostate Cancer Research
Department of Hematology/Oncology and Urology
Taussig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, OH


Terence Friedlander, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco, CA

Elisabeth I. Heath, MD, FACP
Associate Center Director, Translational Sciences
Hartmann Endowed Chair for Prostate Cancer Research
Professor of Oncology
Karmanos Cancer Institute/Wayne State University School of Medicine
Detroit, MI

Alicia Morgans, MD, MPH
Department of Medicine
Hematology and Oncology
Northwestern University
Chicago, IL

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.


In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentations, could be perceived as a potential conflict of interest:

Jame Abraham, MD
  Genentech/Roche Teaching and Speaking
  Pfizer, Inc. Consulting; Teaching and Speaking
Terence Friedlander, MD
  Janssen Independent contractor (including contracted research)
  Astellas Pharma US, Inc. Teaching and Speaking
  Genentech; Pfizer; AstraZeneca Consulting
Jorge A. Garcia, MD, FACP
  Astellas Pharma US, Inc.; Bayer Healthcare; Sanofi Aventis Consulting; Teaching and Speaking
  Clovis Oncology; Exelixis; Genentech/Roche Consulting
Elisabeth I. Heath, MD, FACP
  Sanofi Aventis Membership on advisory committee or review panels; Teaching and Speaking
Alicia Morgans, MD, MPH
  Genentech; Janssen;
Johnson & Johnson
Teaching and Speaking
  AstraZeneca Membership on advisory committee or review panels


All other planners, CME staff, and content reviewers, have no relevant financial relationships to disclose.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:

Astellas and Medivation, Inc., a Pfizer company

This CME activity was produced by
Cleveland Clinic Foundation Center for Continuing Education,
Taussig Cancer Institute and Harborside Press.